Ten23 health’s new General Counsel: Ferdinand Winter

As of March 2025, Ferdinand Winter (pictured) has been appointed General Counsel of Ten23 health, a Swiss pharmaceutical contract development and manufacturing organization.

Moving from Hansa Biopharma, Sweden, Ferdinand will be responsible for establishing and leading Ten23 health’s legal, compliance, and IP practices. In particular this newly created role will entail the creation of new legal processes, the implementation of risk management frameworks, and a further contribution to define corporate governance structures within Ten23 health’s non-hierarchical environment.

The profile

Ferdinand Winter has worked for over a decade in law firms and the life sciences industry. He started his career as a German attorney at law working in Vaduz, Liechtenstein, working at the law firm Kaminski Harmann Patentanwälte from 2012 to 2015.

He then served until 2018 as lead global lawyer for technical operations at Basilea Pharmaceutica, Basel, Switzerland marking his first experience in the pharma sector.

Following that same sectorial path, in 2018 Winter moved to Basel-based pharmaceutical manufacturing company Novartis. During his time at Novartis, he worked as legal counsel for NTO transactions, a role that he eventually covered at senior level until 2020.

Most recently, Winter played a central in building the legal, compliance, and IP function at Hansa Biopharma, a publicly traded Swedish biotech company in his role as General Counsel from 2020 until the end of 2024

The company

Headquartered in Basel, with manufacturing facilities in Visp, in the Valais region of Switzerland, ten23 health partners with pharmaceutical companies and biotech start-ups to support the development of innovative medicines. The company specializes in formulation, analytical and process development, sterile manufacturing, and testing, ensuring that injectable treatments are stable, safe, and effective for patients.